Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis

Trial Profile

Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Alogliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SPEAD-A
  • Most Recent Events

    • 01 Feb 2018 Results of post hoc subanalysis (n=322) evaluating the effect of alogliptin on the longitudinal change in GSM in patients with type 2 diabetes, published in the Diabetes Therapy
    • 25 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2015 Results published in the Diabetes Care
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top